The evolution of approaches to the diagnosis and treatment of patients with Barrett’s esophagus
https://doi.org/10.31146/1682-8658-ecg-175-3-102-107
Abstract
Barrett’s esophagus is one of the most serious complications of gastroesophageal reflux disease also known as GERD. Late diagnosis and treatment cause a high risk of developing adenocarcinoma of the esophagus with the background of Barrett’s esophagus. Today, this condition is one of the most controversial diseases of the gastrointestinal tract (GIT), requiring a careful approach to diagnosis and treatment by a group of specialists, including an endoscopist, gastroenterologist and pathologist. This article is a review of the literature on the history and current aspects of the diagnosis and treatment of Barrett’s esophagus.
About the Authors
S. I. Berdnikov
The Federal State-Financed Institution Federal Siberian Research Clinical Centre under the Federal Medical Biological Agency
Russian Federation
Russian Federation
Sergey I. Berdnikov, endoscopist doctor
Krasnoyarsk
A. B. Salmina
Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Alla B. Salmina, D. of Med. Sci., Professor, Head of Department of Biological Chemistry
Krasnoyarsk
V. V. Salmin
Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Vladimir V. Salmin, D. Sc. in Physical and Math. Sci., Professor, Head of Department of medical and biological physics
Krasnoyarsk
N. S. Rudaya
Siberian State Medical University; Medical Centr named after George K. Zherlov
Russian Federation
Russian Federation
Natalya S. Rudaya, D. of Med. Sci., Professor of surgery Department, endoscopist doctor
Krasnoyarsk; Tomsk
E. V. Semichev
The Federal State-Financed Institution Federal Siberian Research Clinical Centre under the Federal Medical Biological Agency
Russian Federation
Russian Federation
Evgeniy V. Semichev, D. of Med. Sci., Head of scientific Department
Krasnoyarsk
References
1. Onuchina E. V. Vozmozhnosti terapevticheskogo vedenija bol’nyh s pishhevodom Barretta. Siberian Medical Journal. 2008; 5: 9–12.
2. Barrett N. R. Chronic peptic ulcer of the esophagus and esophagitis. B. J. Surg. 1950; 38: 175–182.
3. Bremner C. G., Lynch V. P., Ellis H. F. Barrett’s esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery. 1970; 68: 209–216.
4. Spechler S. J., Sharma P., Souza R. F. et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011; 140:1084–1091.
5. Guidelines for the diagnosis and management of Barrett’s columnar lined oesophagus. A report of the working party of the British Society of Gastroenterology. – 2006.
6. Starostin B. D. Pishhevod Barretta: vyjavlenie, monitoring, lechenie. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2003; 3: 84–91.
7. Falk G. W. Gastroesophageal reflux disease and Barrett’s esophagus. Endoscopy. 2001; 33 (2): 109–118.
8. Blot W. J., Devesa S. S., Kneller R. W. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991; 265: 1287–1289.
9. Zlokachestvennye novoobrazovanija v Rossii v 2017 godu (zabolevaemost’ i smertnost’). Kaprin A. D., Stravinskij V. V., Petrova G. V. (red.). Moskva: MNIOI im. P. A. Gercena – filial FGBU «NMIC radiologii» Minzdrava Rossii, 2018: 250 p.
10. Guillem P. G. How to make a barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig. Dis. Sci. 2005; 50 (3): 415–424.
11. Armstrong D. Epidemiology of GERD, Barrett’s esophagus and esophageal cancer. GI Epidemiology. 2014; 119–134.
12. Hage M., Siersema P. D., Van Dekken H. et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett’s oesophagus: a randomised trial. Gut. 2004; 53 (6): 785–790.
13. Vakil N., Van Zanten S., Kahrilas P. et al. The Montreal definition and classifi cation of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101 (8): 1900–1920; quiz 1943.
14. Sharma P., Dent J., Armstrong D. et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterol. 2006; 131: 1392–1399.
15. DePianto D., Coulombe P. A. Intermediate filaments and tissue repair. Exp. Cell Res. 2004; 301 (1): 68–76.
16. Glickman J. N., Ormsby A. H., Gramlich T. L. et al. Interinstitutional variability and eff ect of tissue fi xative on the interpretation of a Barrett cytokeratin 7/20 immunoreactivity pattern in Barrett esophagus. Human Pathology. 2005; 36 (1): 58–65.
17. Sharma N., Srivastava S., Kern F. et al. CEACAM 6, a novel marker for the diagnosis of Barrett’s esophagus. Dis. Esophagus. 2017; 30 (9): 1–5.
18. Goodarzi M., Correa A. M., Ajani J. A. et al. Antiphosphorylated histone H3 expression in Barrett’s esophagus, low-grade dysplasia, high-grade dysplasia and adenocarcinoma. Modern. Pathology. 2009; 22 (12): 1612–1621.
19. Srivastava S., Kern F., Sharma N. et al. FABP1 and Hepar expression levels in Barrett’s esophagus and associated neoplasia in an Asian population. Dig. Liver Dis. 2017; 49 (10): 1104–1109.
20. Phelan J., MacCarthy F., O’Toole D. et al. The mitochondrial genes bak1, fis1 and sfnare linked with alterations in mitochondrial membrane potential in barrett’s esophagus. Int. J. Mol. Sci. 2018; 19 (11): 3483.
21. Kobiashvili M. G., Mihajlova I. A., Shushakova O. V. Pishhevod Barretta: problemy jendoskopicheskogo vyjavlenija i lechenija. Medico-Biological and Socio-Psychological Problems in Emergency Situations. 2012; 3: 24–28.
22. Williamson W. A. Barrett’s ulcer a surgical disease? Thorac. Cardiovasc. Surg. 1992; 103: 2–7.
23. Duvanskij V. A., Knjazev M. V., Pravednikov P. V. Modern aspects of photodynamic therapy of esophageal. Eksp Klin Gastroenterol. 2011;(10):111–6.
24. Dougherty T. J., Gomer C. J., Henderson B. W. et al. Photodynamic Therapy. J. Natl. Cancer Inst. 1998; 90 (12): 889–905.
25. Overholt B. F., Lightdale C. J., Wang K. K. et al. Photodynamic therapy with porfi mer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: international, partially blinded, randomized phase III trial. Gastrointest. Endosc. 2005; 62: 488–498.
26. Pouw R. E., Gondrie J. J., Rygiel A. M. et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am. J. Gastroenterol. 2009; 104: 1366–1373.
Review
For citations:
Berdnikov S.I., Salmina A.B., Salmin V.V., Rudaya N.S., Semichev E.V. The evolution of approaches to the diagnosis and treatment of patients with Barrett’s esophagus. Experimental and Clinical Gastroenterology. 2020;(3):102-107. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-175-3-102-107
Views:
408
Email this article 